Guangdong Wesail Biotech Co., Ltd. of Dongguan at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Guangdong Wesail Biotech Co., Ltd.

Room 403, Building 1, 1 Taoyuan RD, Songshan Lake, Dongguan, Guangdong, 523808 Dongguan

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
Messe Düsseldorf China Ltd.

Hall map

MEDICA 2021 hall map (Hall 3): stand K92

Fairground map

MEDICA 2021 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Our products

Product category: Diagnostic rapid tests

COVID-19 anti-S1 RBD IgG Test Kit

  • The double-antigen sandwich immunochromatography method is intended for the semi-quantitative or quantitative determination of the S-RBD antibodies of COVID-19 convalescent patients or vaccinated patients in human blood.
  • This Assay has been standardized against the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) (NIBSC code: 20/136, BAU/mL).
  • The results of the kit can be interpretated by naked eye or instrument, which can adopt to different using places or requirements.
  • Equipped with the Handheld Colloidalgold Analyzer WS-Si1400, the test can be completed within 15 minutes, which is portable, fast and accurate.

More Less

About us

Company portrait

Guangdong Wesail Biotech Co., Ltd. (WESAIL), with its strong business philosophy of “strive for excellence, truth and reality”, attaches great importance to technology innovation, product technological experiments, and the research of product advancement. The company is committed to supporting IVD diagnostic partners with excellent performance reagents and analyzers, including colloid gold and immunofluorescence platforms.

Based on deep insights into the future industry development trends, WESAIL continuously launches reagents and analyzers meeting customer needs in various disease areas, including cardiovascular, metabolism, fertility, inflammation, diabetes, hormone, brain injury, renal injury, thyroid, tumor marker, etc. By bringing in more convenient, rapid and accurate tests to patients, WESAIL fulfills the essence of POCT products to the world and continues to maintain a leading technology level among players in the global POCT industry. 

At the end of 2019, a new strain of coronavirus was found and quickly accelerated into a global outbreak (named as COVID-19). WESAIL, as a reagent R&D and production organization, shoulders the social responsibility of epidemic prevention and urgently develops testing reagents. In 2020, a colloidal gold test kit for detecting COVID-19 was launched, which greatly shortened the diagnosis time.

WESAIL products are applicable in a wide range of scenarios. By defining the product layouts as subdivided fields and promoting industrial technological innovation, we will set sail with customers and the future!

Company data

Export content > 75%
Number of employees 50-99
Area of business Diagnostic tests